NASH trials recruiting in New York

All NASH trials nationally

Cities in New York

Recruiting trials in New York

• A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
  NCT07221188 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: East Syracuse, New York
• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
  NCT07165028 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Buffalo, New York, Yonkers
• A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
  NCT07221227 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: East Syracuse, New York
• A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
  NCT05519475 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: New York
• A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
  NCT06528314 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · New York: Buffalo, Manhasset, New York, Rochester
• A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
  NCT06215716 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · New York: Buffalo, Manhasset, New York, Rochester
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
  NCT06318169 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · New York: Albany, Carmel, New York
• A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
  NCT06920043 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: New York
• A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
  NCT06419374 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: Albany, New York
• Blood Collection Biorepository for Liver Disease Research
  NCT03025074 · Phase: Not specified · Ages: 7 Years and older · Sex: All (male and female) · New York: Buffalo
• Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
  NCT05332613 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · New York: New York
• Effect of Insulin Lowering on Lipogenesis
  NCT07403604 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · New York: New York
• Human Models of Selective Insulin Resistance: Alpelisib, Part I
  NCT06354088 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · New York: New York
• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
  NCT06632457 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Brooklyn, Laurelton, New York, Rochester
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
  NCT06632444 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: Brooklyn, Laurelton, New York, Rochester
• Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
  NCT05832229 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: New York
• Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
  NCT04054310 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · New York: New York